A study of safety, tolerability and efficacy of Certican in de novo heart transplant (Tx) patients.
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Ciclosporin; Everolimus
- Indications Heart transplant rejection
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 27 Apr 2010 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
- 29 Nov 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History